化合物CC-401 Hydrochloride T5833

Product Introduction
Bioactivity


英文名: CC-401 Hydrochloride

描述: CC-401 Hydrochloride (CC401 HCl) 是 JNK 抑制剂(Ki= 25~50 nM)。

动物实验: To assess the efficacy of JNK signaling inhibition by CC-401 in anti-angiogenic and oxaliplatin combination therapy in a mouse xenograft model, adult (8-10 weeks of age) female severe combined immunodeficient mice (C.B.17 SCID) were used.?To generate tumors, HT29 cells (1 × 10^6 cells) were injected subcutaneously into the left flank of the mice.?When the tumors reached approximately 200 mm^3, mice were divided into eight groups (eight mice per group) for treatment with bevacizumab , oxaliplatin, CC401, and the appropriate combinations of bevacizumab, oxaliplatin and CC-401.?Mice in the bevacizumab treatment group received 5 mg/kg of bevacizumab by intraperitoneal injection every 3 days for 21 days.?The oxaliplatin treatment group was injected intraperitoneally with 5 mg/kg oxaliplatin per week for 2 weeks.?The CC-401 treatment group was injected intraperitoneally 25 mg/kg for every 3 days.?The combination treatment groups received bevacizumab (every 3 days, 5 mg/kg), oxaliplatin (weekly for 2 weeks, 5 mg/kg), and CC-401 (every 3 days, 25 mg/kg).?The control group received saline intraperitoneally.?Tumor volume and body weight were measured every 3 days.?Tumor volume was calculated using the formula V = AB^2/2, where A is the largest diameter and B is the smallest diameter.?Tumor growth delay was calculated as the difference in the time for control and treated tumors to grow from 200 to 800 mm^3.?For tumor growth delay calculations, mice were continued to receive treatments till the tumor volume reached 800 mm^3.?For immunohistochemistry mice were sacrificed after treatments on day 9 for tumor processing and staining.

体外活性: CC-401 in combination with chemotherapy demonstrates synergism in colon cancer cell lines, although synergy is not always hypoxia specific.?A more detailed analysis focused on HT29 and SW620 (responsive), and HCT116 (nonresponsive) lines.?In HT29 and SW620 cells, CC-401 treatment results in greater DNA damage in the sensitive cells.

体内活性: In vivo, potentiation of bevacizumab, oxaliplatin, and the combination by JNK inhibition was confirmed in HT29-derived mouse xenografts, in which tumor growth delay was greater in the presence of CC-401.?Finally, stable introduction of a dominant negative JNK1, but not JNK2, construct into HT29 cells rendered them more sensitive to oxaliplatin under hypoxia, suggesting differing input of JNK isoforms in cellular responses to chemotherapy.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 100 mg/mL (235.33 mM)


关键字: CC 401 Hydrochloride | CC-401 | Inhibitor | JNK | CC401 Hydrochloride | CC 401 | CC401 | inhibit | CC-401 Hydrochloride

相关产品: Medicarpin | TCS JNK 5a | CC-90001 | Panaxydol | d-Epigalbacin | Astragaloside | Astragaloside IV | Anisomycin | (-)-Bornyl acetate | JIP-1 (153-163) acetate(438567-88-5 free base)

相关库: Anti-Neurodegenerative Disease Compound Library | Drug Repurposing Compound Library | ReFRAME Related Library | Anti-Cancer Drug Library | Bioactive Compounds Library Max | Endoplasmic Reticulum Stress Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library

化合物CC-401 Hydrochloride T5833信息由TargetMol中国为您提供，如您想了解更多关于化合物CC-401 Hydrochloride T5833报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途